{"title":"Misleading and Biased Lancet Editorial on Kashmir: What are the Authors Hiding?","authors":"P. Parikh, Satish Bhat, S. Bansal","doi":"10.25259/ijmio_8_2019","DOIUrl":"https://doi.org/10.25259/ijmio_8_2019","url":null,"abstract":"","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126750661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Mukherjee, Soma Mukherjee, Parikshit Sanyal, V. Bharadwaj, S. Sampath, Gunjan
{"title":"Correlation of Biomarkers and Frozen Section Diagnosis with Paraffin Histopathological Diagnosis in Suspected Ovarian Cancer","authors":"T. Mukherjee, Soma Mukherjee, Parikshit Sanyal, V. Bharadwaj, S. Sampath, Gunjan","doi":"10.25259/ijmio_6_2019","DOIUrl":"https://doi.org/10.25259/ijmio_6_2019","url":null,"abstract":"\u0000\u0000Ovarian cancers pose diagnostic dilemma and is problematic for decision making for the gynecological oncologist as well as the pathologist. The use of intra-operative frozen section can aid significantly in decision making and assist in choosing the correct operative path once a mass lesion of ovaries is discovered.\u0000\u0000\u0000\u0000Over a two-year period, 50 cases of Suspected Ovarian cancers were examined by intra- operative frozen section as well as followed up with histopathology in paraffin sections. Results were categorized in two strata—benign and malignant.\u0000\u0000\u0000\u0000A comparison between frozen-section diagnosis and findings on paraffin section showed that the sensitivity of frozen section in diagnosis of malignant lesions is 97.14%, with specificity 93.33%, positive predictive value 97.14% and negative predictive value 93.33%. Among 50 cases, one case was reported as false positive and one was reported as false negative.\u0000\u0000\u0000\u0000Intra-operative frozen section is a highly sensitive and specific modality for the diagnosis of malignant lesions of the ovary.\u0000","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134311181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Complete metabolic response with letrozole and palbociclib in advanced breast cancer","authors":"M. Dhanushkodi, B. Ananthi, Priya Iyer","doi":"10.25259/ijmio_2_2019","DOIUrl":"https://doi.org/10.25259/ijmio_2_2019","url":null,"abstract":"We report a patient with hormone positive, HER2 negative advanced breast cancer with extensive metastasis who achieved complete metabolic remission with letrozole and palbociclib","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"148 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122058122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Bothra, M. Sabaretnam, G. Chand, A. Mishra, G. Agarwal, A. Agarwal
{"title":"Indian Surgeons’ Perspective Regarding Breast-Conserving Surgery: A Cohort Study","authors":"S. Bothra, M. Sabaretnam, G. Chand, A. Mishra, G. Agarwal, A. Agarwal","doi":"10.25259/ijmio_15_2019","DOIUrl":"https://doi.org/10.25259/ijmio_15_2019","url":null,"abstract":"\u0000\u0000Breast-conserving surgery (BCS) has constantly evolved and recently involves many new facets in the form of SLNB, breast oncoplastic surgery, and brachytherapy. Breast surgeons are required to constantly unlearn and learn to keep abreast with the new guidelines. We aimed to study the Indian surgeons’ perspective about BCS.\u0000\u0000\u0000\u0000We mailed a questionnaire containing 20 questions regarding various aspects of BCS to 1200 surgeons. of these, 112 surgeons (40 endocrine surgeons, 40 surgical oncologists, and 32 general surgeons) responded.\u0000\u0000\u0000\u0000We found that surgeons in the 31 to 40-year age group, surgeons with superspecialty training, surgeons working in private setup, and high-volume surgeons (>100 cases/year) were performing more BCS.\u0000\u0000\u0000\u0000Indian surgeons should have more robust training in BCS to increase the rates of BCS in India.\u0000","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123004506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Talwar, S. Bothra, V. Goel, P. Dash, A. Jajodia, K. Domadia, Krishna Choudhary, V. Koyyala
{"title":"Real World Outcomes of Check Point Inhibitors Immunotherapy in Renal and Urothelial Cancers in a Teratiary Care Cancer Center in India","authors":"V. Talwar, S. Bothra, V. Goel, P. Dash, A. Jajodia, K. Domadia, Krishna Choudhary, V. Koyyala","doi":"10.25259/ijmio_1_2019","DOIUrl":"https://doi.org/10.25259/ijmio_1_2019","url":null,"abstract":"\u0000\u0000The real-world data regarding the response rates, tolerability, and toxicities of immunotherapy is very limited. The aim of this study is to analyze these characteristics in patients who have received immunotherapy for metastatic renal cell carcinoma (RCC) or urothelial cancer (UC).\u0000\u0000\u0000\u0000Retrospective review of patients over a year from 2017–2018 diagnosed with metastatic RCC and UC in our institute who received checkpoint inhibitors was done. PFS and OS were calculated.\u0000\u0000\u0000\u0000A total of 16 patients, 11 with metastatic RCC and 5 patients with Metastatic UC were included in this study. All patients were male and Median age was 57.5 years. Median Number of cycles administered was 6. 50% of patients had a partial response to treatment, 16.6% of patients had stable disease and 33.3% of patients had progressive disease. There were no complete responses to therapy. Median Follow up was 9 months. The median PFS of the whole cohort was 6 months, while in RCC was 6 months and in UC was 1 month. Median OS of the whole cohort is 7 months, while the median OS for RCC and UC were 7 months and 3 months respectively. Fatigue was the most common adverse effect noted and Anaemia was the most common hematological side effect seen with immunotherapy in this study.\u0000\u0000\u0000\u0000This is real-world data of the use of the immune checkpoint inhibitors in the resource-limited setting. The benefit of Immune checkpoint inhibitors may in advanced renal cell cancers and Urothelial cancers may be different from that seen in the Western population.\u0000","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"103 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134336923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence: A new era of technological advancement in oncology care","authors":"Randeep K. Singh","doi":"10.25259/IJMIO-13-2019","DOIUrl":"https://doi.org/10.25259/IJMIO-13-2019","url":null,"abstract":"","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129371807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oral cancers – Micronuclei as biomarker of genotoxicity a population-based study to establish usable dynamic cut off limits in tobacco users","authors":"S. Amin, Nilam Patel, B. Chattoo","doi":"10.25259/IJMIO-4-2019","DOIUrl":"https://doi.org/10.25259/IJMIO-4-2019","url":null,"abstract":"Buccal mucosal samples are studied for micronuclei in tobacco users. This was with emphasis in tobacco chewers. Earlier we established protocol for collecting,staining, and analyzing micronuclei (MN) in buccal smears. Samples from over 650 patients were studied for micronuclei. MN( micronuclei ) are used as a biomarker for genotoxicity in tobacco users. This was clearly evidenced by steady increase in frequency of MN from cases with no tobacco habit, cases with tobacco habit, to potentially malignant lesions (PMD )to frank malignancy in various stages. Since all tobacco ab-users do not get cancer and may take considerable time there is a need to identifying susceptible groups. Here one can arbitrarily use outliers. In the current study nearly 20 % are outliers This is a cheaper way and such cases an be subjected to further studies for some well known gene markers or these identified patient outliers can directly warned of thier greater susceptibility.","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128571414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Parikh, T. Sahoo, Randeep K. Singh, B. Ankur, T. Vineet, G. Bhattacharyya, B. Govind, M. Prashant
{"title":"Practical consensus recommendations - Current role of immune response evaluation criteria in solid tumors criteria in the management of cancer patients receiving immunotherapy","authors":"P. Parikh, T. Sahoo, Randeep K. Singh, B. Ankur, T. Vineet, G. Bhattacharyya, B. Govind, M. Prashant","doi":"10.25259/IJMIO-6-2019","DOIUrl":"https://doi.org/10.25259/IJMIO-6-2019","url":null,"abstract":"Response evaluation criteria in solid tumors (RECIST) are a method used to evaluate and document the response to cancer treatment in solid tumors. The availability of a new class of immuneoncology drugs has resulted in the need to modify RECIST criteria methodology. The first leadership immuno-oncology network (LION) master course brought together experts in oncology and immuno-oncology. Six questions were put to the experts and their opinion, supporting evidence, and experience were discussed to arrive at a practical consensus recommendation. n this nascent field, the availability of a practical consensus recommendation developed by experts in the field is of immense value to the community oncologist and other health-care consultants.","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128912353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nanobyte - Perspectives and milestones in molecular biology and immuno-oncology","authors":"Radhika A. Vaishnav","doi":"10.25259/IJMIO-1-2019","DOIUrl":"https://doi.org/10.25259/IJMIO-1-2019","url":null,"abstract":"","PeriodicalId":404266,"journal":{"name":"International Journal of Molecular & Immuno Oncology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132262835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}